终末期肾病血液透析患者并发高血压的影响因素

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (507 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the influencing factors of hypertension in hemodialysis patients with end-stage renal disease. Methods A retrospective analysis method was used to collect the clinical data of 100 patients with end-stage renal disease who underwent hemodialysis in the People’s Hospital of Bozhou from January 2020 to January 2021. According to the incidence of hypertension during dialysis, the patients were divided into the occurrence group and the non-occurrence group. The clinical data of the two groups were collected, and the influencing factors of hypertension complicated by end-stage renal disease hemodialysis patients were analyzed. Results Among the 100 patients with end-stage renal disease, a total of 76 cases were complicated with hypertension during hemodialysis, accounting for 76.00%. The proportion of patients using erythropoietin (EPO) in the occurrence group was higher than that in the non-occurrence group, while the levels of serum C-reactive protein (CRP), homocysteine (Hcy), and phosphorus (P) were higher than those in the non occurrence group, and the differences were statistically significant (P ＜ 0.05). Logistic regression analysis showed that, the use of EPO and the excessive production of CRP, Hcy, and P were the risk factors of hypertension in hemodialysis patients with end-stage renal disease (OR ＞ 1, P ＜ 0.05). Conclusion Hemodialysis patients with end-stage renal disease have a higher risk of hypertension, the use of EPO, excessive production of serum CRP, Hcy, and P are the influencing factors of hypertension in hemodialysis patients with end-stage renal disease.

Key words： End stage renal disease Hemodialysis Hypertension Erythropoietin C-reactive protein Homocysteine Blood phosphorus

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Lihong WU Han▲ LIU Fang CHENG Li

Cite this article:

ZHANG Lihong WU Han▲ LIU Fang CHENG Li. Influencing factors of hypertension in hemodialysis patients with end-stage renal disease#br#[J]. 中国医药导报, 2022, 19(13): 100-103.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I13/100

[1] Milo G，Bogner I，Bathish Y，et al. Hemodialysis：Present Innovations for Patients’ Future [J]. Harefuah，2017，156（9）：595-599.
[2] Fadili W，Adnouni A，Laouad I. Hemodialysis safety：Evaluation of clinical practice [J]. Saudi J Kidney Dis Transpl，2016，27（3）：553-556.
[3] 陈廷芳，王逸申，盛晓华，等.糖尿病肾病致终末期肾病维持性血液透析患者高血压的多中心临床研究[J].上海医学，2017，40（1）：26-30.
[4] 甘林望，李乾程，温向琼，等.维持性血液透析合并高血压患者难治性高血压的影响因素分析[J].中国现代医学杂志，2016，26（5）：105-109.
[5] 中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].中华内分泌代谢杂志，2015，31（5）：379-385.
[6] 葛均波，徐永健，王辰.内科学[M].9版.北京：人民卫生出版社，2018.
[7] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治，2019，19（1）：1-44.
[8] 袁华财，张甜甜，郭冬梅，等.微型营养评价量表在社区老年人群中的信效度评价[J].山东大学学报（医学版），2018，56（9）：77-82.
[9] Flythe JE，Bansal N. The relationship of volume overload and its control to hypertension in hemodialysis patients [J]. Semin Dial，2019，32（8）：500-506.
[10] 孟甲，魏芳，毕学青，等.维持性血液透析患者并发高血压的相关因素分析[J].江苏医药，2016，42（9）：1037-1039.
[11] 夏凤芝，孙畅.维持性血液透析患者并发高血压的影响因素分析[J].现代仪器与医疗，2018，24（3）：84-85，88.
[12] Georgianos PI，Agarwal R. Systolic and diastolic hypertension among patients on hemodialysis：Musings on volume overload，arterial stiffness，and erythropoietin [J]. Semin Dial，2019，32（6）：507-512.
[13] Agarwal R. Mechanisms and mediators of hypertension induced by erythropoietin and related molecules [J]. Nephrol Dial Transplant，2017，33（10）：1690-1698.
[14] 刘军，罗立剑.新发高血压人群促红细胞生成素与动脉僵硬程度相关性研究[J].西北国防医学杂志，2016，37（2）：105-108.
[15] 方勇，王其海.血清Hcy与hs-CRP水平对高血压及冠心病患者的影响分析[J].陕西医学杂志，2017，46（12）：1657-1658，1661.
[16] Avan A，Tavakoly Sany SB，Ghayour-Mobarhan M，et al. Serum C-reactive protein in the prediction of cardiovascular diseases：Overview of the latest clinical studies and public health practice [J]. J Cell Physiol，2018，233（1）：8508-8525.
[17] Mazidi M，Toth PP，Banach M. C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome， Hypertension， and Diabetes Mellitus in US Adults [J]. Angiology，2018，69（5）：438-442.
[18] Kansui Y，Matsumura K，Morinaga Y，et al. C-reactive protein and incident hypertension in a worksite population of Japanese men [J]. J Clin Hypertens（Greenwich），2019，21（4）：524-532.
[19] 刘方方，张强，杨丽红，等.原发性高血压病患者血清超敏C反应蛋白和同型半胱氨酸与夜间血压变异性的关系研究[J].中国全科医学，2020，23（10）：1292-1297.
[20] 蒯琳，洪梅.血清同型半胱氨酸，高敏C反应蛋白，胱抑素C水平与冠状动脉粥样硬化的关系[J].中国医药导报，2018，15（35）：58-61.
[21] Weber GJ，Pushpakumar S，Tyagi SC，et al. Homocysteine and hydrogen sulfide in epigenetic，metabolic and microbiota related renovascular hypertension [J]. Pharmacol Res，2016，113（Pt A）：300-312.
[22] Onyemelukwe OU，Maiha BB. Relationship between plasma homocysteine and blood pressure in hypertensive Northern-Nigerians [J]. Afr Health Sci，2020，20（1）：324-337.
[23] 刘国星，杨波.原发性高血压患者血清25羟基维生素D，同型半胱氨酸及载脂蛋白B/A1变化的价值研究[J].国际检验医学杂志，2018，39（12）：1463-1466.
[24] Kim H，Mizuno M，Vongpatanasin W. Phosphate，the forgotten mineral in hypertension [J]. Curr Opin Nephrol Hypertens，2019，28（4）：345-351.
[25] 杨倩，查兵兵，刘军，等.Graves病患者血清磷水平与甲状腺功能的相关分析[J].临床内科杂志，2019，36（10）：685-688.